Compare TIPT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TIPT | ENGN |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.2M | 605.5M |
| IPO Year | 2007 | N/A |
| Metric | TIPT | ENGN |
|---|---|---|
| Price | $17.67 | $9.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.71 |
| AVG Volume (30 Days) | 198.1K | ★ 461.0K |
| Earning Date | 03-02-2026 | 03-09-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 17.79 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $2,070,076,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.40 | ★ N/A |
| Revenue Growth | ★ 4.25 | N/A |
| 52 Week Low | $17.07 | $2.65 |
| 52 Week High | $27.41 | $12.25 |
| Indicator | TIPT | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 53.30 |
| Support Level | $17.26 | $9.30 |
| Resistance Level | $17.81 | $10.20 |
| Average True Range (ATR) | 0.37 | 0.88 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 29.72 | 41.30 |
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.